{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:19:06Z","timestamp":1790705946822,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Celgene Cellular Therapeutics","award":["CA-093897"],"award-info":[{"award-number":["CA-093897"]}]},{"name":"National Cancer Institute","award":["CA55819"],"award-info":[{"award-number":["CA55819"]}]},{"name":"National Cancer Institute","award":["CA113992"],"award-info":[{"award-number":["CA113992"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human placenta has emerged as a valuable source of transplantable cells of mesenchymal and hematopoietic origin for multiple cytotherapeutic purposes, including enhanced engraftment of hematopoietic stem cells, modulation of inflammation, bone repair, and cancer. Placenta-derived adherent cells (PDACs) are mesenchymal-like stem cells isolated from postpartum human placenta. Multiple myeloma is closely associated with induction of bone disease and large lytic lesions, which are often not repaired and are usually the sites of relapses. We evaluated the antimyeloma therapeutic potential, in vivo survival, and trafficking of PDACs in the severe combined immunodeficiency (SCID)\u2013rab model of medullary myeloma-associated bone loss. Intrabone injection of PDACs into nonmyelomatous and myelomatous implanted bone in SCID-rab mice promoted bone formation by stimulating endogenous osteoblastogenesis, and most PDACs disappeared from bone within 4 weeks. PDACs inhibitory effects on myeloma bone disease and tumor growth were dose-dependent and comparable with those of fetal human mesenchymal stem cells (MSCs). Intrabone, but not subcutaneous, engraftment of PDACs inhibited bone disease and tumor growth in SCID-rab mice. Intratumor injection of PDACs had no effect on subcutaneous growth of myeloma cells. A small number of intravenously injected PDACs trafficked into myelomatous bone. Myeloma cell growth rate in vitro was lower in coculture with PDACs than with MSCs from human fetal bone or myeloma patients. PDACs also promoted apoptosis in osteoclast precursors and inhibited their differentiation. This study suggests that altering the bone marrow microenvironment with PDAC cytotherapy attenuates growth of myeloma and that PDAC cytotherapy is a promising therapeutic approach for myeloma osteolysis.<\/jats:p>","DOI":"10.1002\/stem.572","type":"journal-article","created":{"date-parts":[[2010,11,23]],"date-time":"2010-11-23T19:18:58Z","timestamp":1290539938000},"page":"263-273","source":"Crossref","is-referenced-by-count":71,"title":["Human Placenta-Derived Adherent Cells Prevent Bone loss, Stimulate Bone formation, and Suppress Growth of Multiple Myeloma in Bone"],"prefix":"10.1093","volume":"29","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ling","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pennisi","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Wang","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Heidaran","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Pal","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"He","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Abbot","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Faleck","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hariri","sequence":"additional","affiliation":[{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijay","family":"Nair","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Epstein","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Yaccoby","sequence":"additional","affiliation":[{"name":"Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,24]]},"reference":[{"key":"2022011210352097200_bib1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022011210352097200_bib2","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"2022011210352097200_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"2022011210352097200_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"2022011210352097200_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"2022011210352097200_bib6","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"2022011210352097200_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.20774","article-title":"Role of osteoblast suppression in multiple myeloma","volume":"98","author":"Stewart","year":"2006","journal-title":"J Cell Biochem"},{"key":"2022011210352097200_bib8","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"2022011210352097200_bib9","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"2022011210352097200_bib10","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"2022011210352097200_bib11","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"2022011210352097200_bib12","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: Possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"2022011210352097200_bib13","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"2022011210352097200_bib14","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"2022011210352097200_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"2022011210352097200_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"2022011210352097200_bib17","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors","volume":"23","author":"Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"2022011210352097200_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1","article-title":"Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients","volume":"91","author":"Wallace","year":"2001","journal-title":"Cancer"},{"key":"2022011210352097200_bib19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.hoc.2007.08.007","article-title":"The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies","volume":"21","author":"Mitsiades","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"2022011210352097200_bib20","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2006-03-013433","article-title":"Clinical trials with adult stem\/progenitor cells for tissue repair: Let's not overlook some essential precautions","volume":"109","author":"Prockop","year":"2007","journal-title":"Blood"},{"key":"2022011210352097200_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells","volume":"284","author":"Pittenger","year":"1999","journal-title":"Science"},{"key":"2022011210352097200_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nri2395","article-title":"Mesenchymal stem cells in health and disease","volume":"8","author":"Uccelli","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"2022011210352097200_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.clpt.6100313","article-title":"\u201cStemness\u201d does not explain the repair of many tissues by mesenchymal stem\/multipotent stromal cells (MSCs)","volume":"82","author":"Prockop","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"2022011210352097200_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat Med"},{"key":"2022011210352097200_bib25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1634\/stemcells.2007-0594","article-title":"Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international Workshop on Placenta Derived Stem Cells","volume":"26","author":"Parolini","year":"2008","journal-title":"Stem Cells"},{"key":"2022011210352097200_bib26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/14712598.8.8.1241","article-title":"Placental-derived and expanded mesenchymal stromal cells (PLX-I) to enhance the engraftment of hematopoietic stem cells derived from umbilical cord blood","volume":"8","author":"Prather","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"2022011210352097200_bib27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: A novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"2022011210352097200_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/stemcells.2004-0098","article-title":"Isolation of multipotent cells from human term placenta","volume":"23","author":"Yen","year":"2005","journal-title":"Stem Cells"},{"key":"2022011210352097200_bib29","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/scd.2007.0154","article-title":"Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells","volume":"17","author":"Barlow","year":"2008","journal-title":"Stem Cells Dev"},{"key":"2022011210352097200_bib30","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1634\/stemcells.22-5-649","article-title":"Human placenta-derived cells have mesenchymal stem\/progenitor cell potential","volume":"22","author":"Fukuchi","year":"2004","journal-title":"Stem Cells"},{"key":"2022011210352097200_bib31","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"2022011210352097200_bib32","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"2022011210352097200_bib33","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2007.06742.x","article-title":"Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines","volume":"138","author":"Li","year":"2007","journal-title":"Br J Haematol"},{"key":"2022011210352097200_bib34","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"2022011210352097200_bib35","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"2022011210352097200_bib36","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"key":"2022011210352097200_bib37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"2022011210352097200_bib38","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: Myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"2022011210352097200_bib39","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"2022011210352097200_bib40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/mt.2009.62","article-title":"Repair of tissues by adult stem\/progenitor cells (MSCs): Controversies, myths, and changing paradigms","volume":"17","author":"Prockop","year":"2009","journal-title":"Mol Ther"},{"key":"2022011210352097200_bib41","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood.V77.12.2688.2688","article-title":"Role of bone marrow stromal cells in the growth of human multiple myeloma","volume":"77","author":"Caligaris-Cappio","year":"1991","journal-title":"Blood"},{"key":"2022011210352097200_bib42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14653240802486517","article-title":"The (in) auspicious role of mesenchymal stromal cells in cancer: Be it friend or foe","volume":"10","author":"Kidd","year":"2008","journal-title":"Cytotherapy"},{"key":"2022011210352097200_bib43","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20051921","article-title":"Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma","volume":"203","author":"Khakoo","year":"2006","journal-title":"J Exp Med"},{"key":"2022011210352097200_bib44","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","article-title":"The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth","volume":"114","author":"Pennisi","year":"2009","journal-title":"Blood"},{"key":"2022011210352097200_bib45","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo","volume":"111","author":"Edwards","year":"2008","journal-title":"Blood"},{"key":"2022011210352097200_bib46","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"key":"2022011210352097200_bib47","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/stem.187","article-title":"Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging","volume":"27","author":"Kidd","year":"2009","journal-title":"Stem Cells"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.572","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/29\/2\/263\/41966170\/stmcls_29_2_263.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/29\/2\/263\/41966170\/stmcls_29_2_263.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T03:10:01Z","timestamp":1642561801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/29\/2\/263-273\/6403521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2,24]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.572","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2,1]]},"published":{"date-parts":[[2011,2,1]]}}}